{"id":25360,"date":"2025-04-04T22:32:02","date_gmt":"2025-04-04T22:32:02","guid":{"rendered":"http:\/\/medexperts.pro\/?p=25360"},"modified":"2025-04-04T23:25:05","modified_gmt":"2025-04-04T23:25:05","slug":"trump-rejects-proposal-for-medicare-to-cover-wegovy-and-other-obesity-drugs","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=25360","title":{"rendered":"Trump Rejects Proposal for Medicare to Cover Wegovy and Other Obesity Drugs"},"content":{"rendered":"
<\/div>\n

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access to weight-loss drugs paid for Medicare and Medicaid.<\/p>\n

\n
\n
\n

The Trump administration on Friday rejected a Biden plan that would have required Medicare and Medicaid to cover obesity drugs and expanded access for millions of people.<\/p>\n

Under the law that established Medicare\u2019s Part D drug benefits, the program was forbidden from paying for drugs for \u201cweight loss.\u201d The Biden administration\u2019s proposal last November<\/a> had attempted to sidestep that ban by arguing that the drugs would be allowed to treat the disease of obesity and its related conditions.<\/p>\n

Expanding coverage of the drugs would have cost the federal government billions of dollars. The Biden administration estimated the federal expense at about $35 billion over 10 years.<\/p>\n

The decision announced Friday was part of a larger 438-page regulation<\/a> updating parts of the programs through which beneficiaries get drug and private medical coverage. The latest revision did not explain why Medicare should not cover the drugs.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

Catherine Howden, a spokeswoman for the Centers for Medicare and Medicaid Services, said in an email that the agency believes expanding coverage \u201cis not appropriate at this time.\u201d But she said the agency had not ruled out coverage and \u201cmay consider future policy options\u201d for the drugs.<\/p>\n

The most popular weight loss drugs come from Novo Nordisk, which sells its medicine as Wegovy for weight loss and as Ozempic for diabetes, and from Eli Lilly, which sells its product as Zepbound for weight loss and Mounjaro for diabetes.<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access to weight-loss drugs paid for Medicare and Medicaid.The Trump administration on Friday rejected a Biden plan that would have required Medicare and Medicaid to cover obesity drugs and expanded access for millions of people.Under the law that established Medicare\u2019s Part D drug benefits, the program was forbidden from paying for drugs for \u201cweight loss.\u201d The Biden administration\u2019s proposal last November had attempted to sidestep that ban by arguing that the drugs would be allowed to treat the disease of obesity and its related conditions.Expanding coverage of the drugs would have cost the federal government billions of dollars. The Biden administration estimated the federal expense at about $35 billion over 10 years.The decision announced Friday was part of a larger 438-page regulation updating parts of the programs through which beneficiaries get drug and private medical coverage. The latest revision did not explain why Medicare should not cover the drugs.Catherine Howden, a spokeswoman for the Centers for Medicare and Medicaid Services, said in an email that the agency believes expanding coverage \u201cis not appropriate at this time.\u201d But she said the agency had not ruled out coverage and \u201cmay consider future policy options\u201d for the drugs.The most popular weight loss drugs come from Novo Nordisk, which sells its medicine as Wegovy for weight loss and as Ozempic for diabetes, and from Eli Lilly, which sells its product as Zepbound for weight loss and Mounjaro for diabetes.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":25362,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-25360","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/25360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25360"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/25360\/revisions"}],"predecessor-version":[{"id":25363,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/25360\/revisions\/25363"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/25362"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}